利拉鲁肽+达格列净治疗糖尿病肾病的疗效探究  

Explore the Efficacy of Liraglutide+Dapagliflozin in the Treatment of Diabetic Nephropathy

作　　者：李芬芬 齐瑞 LI Fenfen;QI Rui(Department of Nephrology,Shandong Guoxin Yiyang Group Zaozhuang Central Hospital,Zaozhuang 277000,Shan-dong,China)

机构地区：[1]山东国欣颐养集团枣庄中心医院肾内科,山东枣庄277000

出　　处：《糖尿病新世界》2024年第23期21-24,共4页Diabetes New World

摘　　要：目的 探讨糖尿病肾病患者采用利拉鲁肽+达格列净治疗的效果。方法 选取2022年5月-2024年6月山东国欣颐养集团枣庄中心医院接收的60例糖尿病肾病患者,按照治疗方法不同分为两组,各30例。对照组进行利拉鲁肽治疗,研究组进行利拉鲁肽+达格列净治疗。对比两组治疗总有效率、胰岛功能指标、血糖指标以及炎性因子指标水平。结果 与对照组比较,研究组治疗总有效率更高,差异有统计学意义(P<0.05)。治疗后,与对照组比较,研究组餐后2 h胰岛素、空腹胰岛素、胰岛β细胞功能指数、胰岛素抵抗指数均更优,差异均有统计学意义(P均<0.05)。治疗后,与对照组比较,研究组空腹血糖、糖化血红蛋白、餐后2 h血糖水平均更低,差异均有统计学意义(P均<0.05)。治疗后,与对照组比较,研究组白细胞介素-1β、超敏C反应蛋白、肿瘤坏死因子-α水平均更低,差异均有统计学意义(P均<0.05)。结论 应用利拉鲁肽联合达格列净,可以显著提高糖尿病肾病患者的临床效果,改善血糖和胰岛素分泌,并减少炎症反应。Objective To investigate the effect of liraglutide+dapagliflozin in patients with diabetic nephropathy.Methods From May 2022 to June 2024,60 patients with diabetic nephropathy admitted to Shandong Guoxin Yiyang Group Zaozhuang Central Hospital were selected.They were divided into two groups according to different treatment methods,30 cases in each group.The control group was treated with liraglutide,and the study group was treated with liraglutide+dapagliflozin.The total effective rate,islet function indexes,the levels of blood glucose indexes and inflam-matory factor indexes were compared between the two groups.Results Compared with the control group,the total effec-tive rate of the study group was higher,and the difference was statistically significant(P<0.05).After treatment,com-pared with the control group,the 2-hour postprandial insulin,fasting insulin,isletβcell function index and insulin re-sistance index of the study group were better,and the differences were statistically significant(all P<0.05).After treat-ment,compared with the control group,the levels of fasting blood glucose,glycated hemoglobin A1c and 2-hour post-prandial blood glucose in the study group were lower,and the differences were statistically significant(all P<0.05).Af-ter treatment,compared with the control group,the levels of interleukin-1β,high-sensitivity C-reactive protein and tumor necrosis factor-αin the study group were lower,and the differences were statistically significant(all P<0.05).Conclusion The application of liraglutide combined with dapagliflozin can significantly improve the clinical effect of patients with diabetic nephropathy,improve blood glucose and insulin secretion,and reduce inflammatory response.

关 键 词：达格列净 利拉鲁肽 糖尿病肾病 临床疗效 

分 类 号：R59[医药卫生—内科学]